Zolpidem use reduces Pittsburgh Sleep Quality Index (PSQI) scores, suggesting its efficacy for insomnia in patients with solid tumours, a study has shown. Though not as effective as zolpidem, sleep hygiene counseling slightly improves overall sleep.
Sodium-glucose transport protein 2 (SGLT2) inhibitors exert a putative epigenetic regulation of the protecting cardiovascular effect, reports a study, adding that dapagliflozin may protect the kidneys by preserving renal vasodilating capacity.
Using a standardized beta-lactam allergy questionnaire as a pharmacy education tool can significantly reduce utilization of aztreonam in terms of doses, therapy days and de-escalations, reports a study.
The 30-day all-cause mortality is similar between definitive therapy with vancomycin or a beta-lactam among patients with an ampicillin-susceptible enterococcal bloodstream infection (BSI), a recent study has shown.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.
The addition of ticagrelor to aspirin significantly reduced ischaemic events but led to an upsurge in major bleeding events relative to aspirin alone in individuals with stable coronary artery disease (CAD) and type 2 diabetes (T2D) without prior myocardial infarction (MI) or stroke. However, there was a favourable net clinical benefit in a subgroup with prior percutaneous coronary intervention (PCI), according to the results of the THEMIS* and THEMIS-PCI trials presented at the ESC Congress 2019.
In the treatment of atrial fibrillation or flutter, the class III antiarrhythmic drug dronedarone is safe and effectively delays recurrence in patients regardless of whether they have undergone cardioversion or not, according to a posthoc analysis presented at the European Society of Cardiology (ESC) Congress 2019.
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.